Apogee Therapeutics, Inc. Common Stock
APGEApogee Therapeutics, Inc. (APGE) is a biopharmaceutical company focused on the development of targeted therapies for immune-mediated diseases. The company's pipeline emphasizes innovative treatments aimed at improving patient outcomes in areas such as inflammatory and autoimmune disorders.
Company News
Apogee Therapeutics reported positive Phase 1 trial results for APG333, a novel half-life extended TSLP antibody, demonstrating a 55-day half-life and potential for quarterly dosing in respiratory treatments.
Apogee Therapeutics, a clinical-stage biotech company, announced a secondary stock offering of approximately 6.95 million shares at $41 per share, potentially raising around $300 million for preclinical studies, clinical trials, and research and development activities.
Apogee Therapeutics Inc CEO Michael Henderson sold 15,000 shares of the company, reducing his ownership to 1,474,487 shares. The transaction could be of interest to investors tracking insider behaviors as an indicator of company performance and future stock movement.
Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price actio...
